510(k) for Medic-Aid's new inhaler:
This article was originally published in Clinica
UK company Medic-Aid has received clearance from the US FDA for its HaloLite inhaled drug delivery system. The device uses an adaptive aerosol delivery technology which closely monitors the patient's breathing pattern and delivers the drug only during inspiration - shutting down after the pre-set dose has been administered. This way, the company says, HaloLite consistently delivers a precise dose to the lung. The product has been CE-marked and US clinical studies are to begin in the first half of this year.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.